Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday. Several other analysts also recently commented on CPRX. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a […]
Summit Global Investments Lowers Stake in Catalyst Pharmaceuticals, Inc (NASDAQ:CPRX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have received an average recommendation of “Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the […]
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 5,830,000 shares, a drop of 9.9% from the February 29th total of 6,470,000 shares. Approximately 5.8% of the company’s shares are sold short. Based on an […]
Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […]